Literature DB >> 21812332

A toxicological evaluation of a claudin modulator, the C-terminal fragment of Clostridium perfringens enterotoxin, in mice.

H Suzuki1, M Kondoh, X Li, A Takahashi, K Matsuhisa, K Matsushita, Y Kakamu, S Yamane, M Kodaka, K Isoda, K Yagi.   

Abstract

Tight junctions (TJs) maintain cellular polarity between the apical and basolateral region of epithelial cells. Claudin, a tetra-transmembrane protein, plays a pivotal role in the barrier function of TJs. We previously found that a claudin modulator, the C-terminal fragment of Clostridium perfringens enterotoxin (C-CPE), may be a promising candidate for improving the mucosal absorption of drugs. C-CPE is a fragment of enterotoxin, and putative CPE claudin receptors are highly expressed in liver and kidney. The safety and antigenicity of C-CPE must be evaluated for future clinical application. Therefore, we evaluated whether C-CPE administration in mice leads to tissue injury or production of antibodies. Intravenous administration of C-CPE at 5 mg/kg, which is a more than 25-fold higher dose than that used in a murine mucosal absorption model, did not increase biochemical markers of liver and kidney injury even after 11 injections once a week. Nasal C-CPE administration (2 mg/kg) once a week for 11 administrations also did not increase these biochemical markers, but 6 administrations of C-CPE resulted in elevation of C-CPE-specific serum IgG. These results indicate that development of a less antigenic claudin modulator will be essential for future clinical application of a C-CPE-based mucosal absorption enhancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21812332

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  10 in total

Review 1.  Molecular Sensing with Host Systems for Hyperpolarized 129Xe.

Authors:  Jabadurai Jayapaul; Leif Schröder
Journal:  Molecules       Date:  2020-10-11       Impact factor: 4.411

2.  C-Terminal Clostridium perfringens Enterotoxin-Mediated Antigen Delivery for Nasal Pneumococcal Vaccine.

Authors:  Hidehiko Suzuki; Akihiro Watari; Eri Hashimoto; Miki Yonemitsu; Hiroshi Kiyono; Kiyohito Yagi; Masuo Kondoh; Jun Kunisawa
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

3.  Effect of Clostridium perfringens enterotoxin on gastric cancer cells SGC7901 which highly expressed claudin-4 protein.

Authors:  Zheng-Yun Liang; Xing Kang; Hong Chen; Meng Wang; Wen-Xian Guan
Journal:  World J Gastrointest Oncol       Date:  2017-04-15

Review 4.  Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes.

Authors:  Maliheh Ghadiri; Paul M Young; Daniela Traini
Journal:  Pharmaceutics       Date:  2019-03-11       Impact factor: 6.321

5.  Use of Modified Clostridium perfringens Enterotoxin Fragments for Claudin Targeting in Liver and Skin Cells.

Authors:  Laura-Sophie Beier; Jan Rossa; Stephen Woodhouse; Sophia Bergmann; Holger B Kramer; Jonas Protze; Miriam Eichner; Anna Piontek; Sabine Vidal-Y-Sy; Johanna M Brandner; Gerd Krause; Nicole Zitzmann; Jörg Piontek
Journal:  Int J Mol Sci       Date:  2019-09-26       Impact factor: 5.923

6.  Claudin-5 binder enhances focused ultrasound-mediated opening in an in vitro blood-brain barrier model.

Authors:  Liyu Chen; Ratneswary Sutharsan; Jonathan Lf Lee; Esteban Cruz; Blaise Asnicar; Tishila Palliyaguru; Joanna M Wasielewska; Arnaud Gaudin; Jae Song; Gerhard Leinenga; Jürgen Götz
Journal:  Theranostics       Date:  2022-01-31       Impact factor: 11.556

Review 7.  Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs.

Authors:  Andrew Lofts; Fahed Abu-Hijleh; Nicolette Rigg; Ram K Mishra; Todd Hoare
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

8.  Identification of claudin-4 binder that attenuates tight junction barrier function by TR-FRET-based screening assay.

Authors:  Akihiro Watari; Miki Kodaka; Koji Matsuhisa; Yuta Sakamoto; Kota Hisaie; Norihito Kawashita; Tatsuya Takagi; Yoshiaki Yamagishi; Hidehiko Suzuki; Hirofumi Tsujino; Kiyohito Yagi; Masuo Kondoh
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

9.  Development of Adjuvant-Free Bivalent Food Poisoning Vaccine by Augmenting the Antigenicity of Clostridium perfringens Enterotoxin.

Authors:  Hidehiko Suzuki; Koji Hosomi; Ayaka Nasu; Masuo Kondoh; Jun Kunisawa
Journal:  Front Immunol       Date:  2018-10-09       Impact factor: 7.561

10.  Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting.

Authors:  Hobin Yang; Hayeon Park; Yong Jin Lee; Jun Young Choi; TaeEun Kim; Nirmal Rajasekaran; Saehyung Lee; Kyoung Song; Sungyoul Hong; Joon-Seok Choi; Hyunbo Shim; Young-Deug Kim; Soohyun Hwang; Yoon-La Choi; Young Kee Shin
Journal:  Biomolecules       Date:  2019-12-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.